Search Results
Sep 25, 2025, 14:05 ET Axon Therapies Raises $32M in Oversubscribed Series A to Transform Heart Failure Treatment
co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation by existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.
More news about: Axon Therapies
Sep 25, 2025, 11:10 ET Harness Named a Leader in the 2025 Gartner® Magic Quadrant™ for DevOps Platforms For the Second Consecutive Year
strategy enables Harness to meet the evolving needs of engineering teams without adding complexity or overhead. Whether organizations are modernizing CI/CD, strengthening security posture, optimizing cloud spend, or improving developer experience, Harness provides a modular, extensible foundation to support
More news about: Harness
Sep 25, 2025, 10:00 ET clinicasdelhombre.com abre una nueva sede para cuidar tu salud sin complicaciones en Satélite, Estado de México.
Edificio Cristal: Federico T. de la Chica 17, Cd. Satélite, la nueva sede ofrece un espacio cómodo, moderno y diseñado para brindar atención especializada a hombres que buscan hacerse cargo de
More news about: elery.co
Sep 25, 2025, 09:00 ET Appknox and CredShields Partner to Deliver Unified Security Across Mobile and Web3 Ecosystems
2000 companies and government organizations across 60+ countries, Appknox specializes in detecting AI vulnerabilities and seamlessly integrates with CI/CD pipelines. Our enterprise-grade solutions help financial services, healthcare, and retail organizations meet global compliance requirements while protecting
More news about: Appknox
Sep 25, 2025, 08:01 ET Breakthrough T1D, Lupus Research Alliance, and National Multiple Sclerosis Society Award Recipients of First Common Mechanisms of Autoimmunity Insight Award
of MedicineDr. Voss is looking at how disrupting a key receptor that transports iron, CD71, could rebalance the immune system. Dr. Voss has generated anti-CD71 nanobodies – a smaller type of antibody – made in alpacas. These nanobodies will be tested in mouse models of autoimmune
More news about: Lupus Research Alliance
Sep 24, 2025, 18:04 ET CD Valet Launches Interactive CD Rate Map, Helping Savers Make the Most of their Money
little visibility into where to find the highest CD rates. CD Valet, the most comprehensive resource for current CD rates across the country, looks to eliminate that gap, ensuring savers can easily find the best CD rates and terms available. "CD Valet aims to help savers make more money on their
More news about: CD Valet
Sep 24, 2025, 16:05 ET Synopsys Collaborates with TSMC to Enable 2D and 3D Design Solutions
Ansys PathFinder-SC™ is a newly certified electrostatic discharge current density (ESD CD) / Point-to-Point (P2P) checker for the N2P process, validating chip resilience against electrical overstress surges and instilling confidence in engineering
More news about: Synopsys, Inc.
Sep 24, 2025, 09:04 ET NUCALM IGNITES THE POWER OF VOICE WITH CELEBRATED COACH ROGER LOVE
voice coach in history has been more commercially successful in both the speaking and singing fields. Love has vocally produced more than 100 million CD sales worldwide, written three top selling books, created numerous best-selling audio and video programs, and appeared as a regular in four major network
More news about: NuCalm
Sep 24, 2025, 09:02 ET Immorta Bio Reports Preclinical Activity of Senolytic Immunotherapy SenoVax™ in a Chronic Traumatic Encephalopathy (CTE) Model
control across lung, breast, glioma, and pancreatic settings, synergy with checkpoint inhibitors, and immune rejuvenation signals (CD8/NK activity). Immorta Bio has filed an IND to begin clinical evaluation of SenoVax™ in advanced non–small cell lung cancer (NSCLC) and is
More news about: Immorta Bio, Inc.
Sep 24, 2025, 09:00 ET Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
drug development. Both CellCarta and Lunit have focused on enabling immune phenotype analysis — CellCarta, via IHC stains including panCK and CD8, and Lunit, via AI analysis of H&E with its Lunit SCOPE IO® product. Each service aims to enable the use of quantitative
More news about: Lunit
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
delivered B-cell therapy that provides the flexibility of self-administration for adults with relapsing forms of multiple sclerosis (RMS). It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously7-10. Initial
More news about: Novartis Pharmaceuticals Corporation
Sep 23, 2025, 10:44 ET Testkube Raises $8M Series A to Help Software Quality Keep Pace With AI Development Velocity
development, yet it also makes testing significantly harder," said Dmitry Fonarev, CEO of Testkube. "Traditional testing and CI/CD tools weren't built for AI-driven or cloud-native scale. Testkube gives developers and platform teams the confidence to ship fast without sacrificing
More news about: Testkube
Sep 23, 2025, 10:00 ET From Guesswork to Certainty: Aptori's AI Triage Delivers Deterministic, Actionable Security Findings and Eliminates False Positives
risk. Built for the AI-Code EraAI Triage is designed to meet the realities of modern software delivery. It integrates directly into CI/CD pipelines and coding environments, providing real-time feedback without slowing developers down. Results are deterministic – repeatable, testable and
More news about: Aptori
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP
Sep 23, 2025, 08:35 ET HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
Psoriasis (Pso), asthma, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), Ulcerative Colitis (UC), and Crohn's Disease (CD). www.hkeybio.com High-Resolution
More news about: HKeyBio
Sep 23, 2025, 08:13 ET Ultra-Precision Motion Control and Nanopositioning Solutions at SEMICON West
PI's portfolio of precision solutions supports a wide range of semiconductor processes, including nano-lithography, laser optics integration, mask and CD measurement, wafer inspection, and wafer dicing. Beyond semiconductors, PI technologies drive innovation in silicon photonics, quantum computing, industrial
More news about: PI (Physik Instrumente) LP
Sep 23, 2025, 08:00 ET StackGen Announces Technology Partnership with HashiCorp to Deliver Visual Infrastructure Automation for Enterprise Teams
architecture using StackGen's visual editor, (2) Configure HCP Terraform workspace details, and (3) Deploy generated infrastructure as code through any CI/CD pipeline, with HCP Terraform managing remote state automatically. "HashiCorp has set the gold standard for infrastructure automation. Terraform
More news about: StackGen
Sep 22, 2025, 14:10 ET Omio e České dráhy annunciano una partnership strategica che amplia le opzioni di viaggio in treno attraverso l'Europa
omio.com Informazioni sull'azienda České dráhy, a. s. České dráhy (ČD) è il più grande operatore ferroviario della Repubblica Ceca, con una media di 6.600 treni al giorno. Nel 2024, ČD ha trasportato complessivamente 168,8 milioni di passeggeri. Negli ultimi anni l'azienda ha
More news about: Omio
Sep 22, 2025, 14:06 ET Omio y České dráhy anuncian una alianza estratégica que amplía las opciones de viaje en tren a través de Europa
omio.com Acerca de la empresa České dráhy, a. s. České dráhy (ČD) es el mayor operador ferroviario checo, con una media de 6600 trenes diarios. En 2024, ČD transportó un total de 168,8 millones de pasajeros. En los últimos años, la empresa ha realizado importantes
More news about: Omio
Sep 22, 2025, 13:56 ET Omio geht strategische Partnerschaft mit České dráhy ein und erweitert Angebot für grenzüberschreitende Zugverbindungen in Europa
omio.com. Über České dráhy: České dráhy (ČD) ist der größte tschechische Bahnbetreiber und setzt täglich durchschnittlich 6.600 Züge ein. Im Jahr 2024 beförderte ČD insgesamt 168,8 Millionen Fahrgäste. In den vergangenen Jahren hat das Unternehmen
More news about: Omio
Sep 22, 2025, 13:24 ET Omio and České dráhy announce strategic partnership, elevating European cross-border train travel options
omio.com About the company České dráhy, a. s. České dráhy (ČD) is the largest Czech railway operator, dispatching an average of 6,600 trains every day. In 2024, ČD transported a total of 168.8 million passengers. In recent years, the company has been heavily investing
More news about: Omio
Sep 22, 2025, 09:00 ET Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
known structural information. The new study extends this work to two additional targets, CD98hc and IL-11, bringing the total to eight: PD-L1, HER2, EGFR(S468R mutant), ACVR2A/B, FZD7, ALK7, CD98hc, and IL-11. Notably, IL-11 represents a target without any known antibody complex structure, highlighting
More news about: Galux
Sep 22, 2025, 02:51 ET Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
the extracellular domain of the human TGF-β receptor II. TIGIT is an emerging immune checkpoint, and blocking TIGIT-CD155 interactions can relieve suppression of tumor-infiltrating CD8+ T cells and NK cells, thereby enhancing their anti-tumor activity. TGF-β signaling contributes to immunosuppression,
More news about: Akeso, Inc.
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBody™ platform (a CD3 T-cell engager platform), X-body™ platform (a 4-1BB engager platform), TOPiKinectics™ (ADC platform), which serve as the cornerstone for our continued
More news about: Leads Biolabs
Sep 19, 2025, 17:28 ET TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
a) CD64+ cells are the predominant source of IL-23 in CD. Cells not expressing CD64 may also contribute to IL-23 production but to a lesser extent.2,3b) "Only" based on approved selective IL-23 inhibitors for moderately to severely active UC and CD as of March 2025.4-6c)
More news about: Johnson & Johnson